Desogestrel-Ethinyl Estradiol 28 tablets — Competitive Intelligence Brief

Desogestrel-Ethinyl Estradiol 28 tablets (Desogestrel-Ethinyl Estradiol 28 tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Gynecology.

phase 3 Combined oral contraceptive Progesterone receptor, estrogen receptor Contraception / Gynecology Small molecule

Target snapshot

Desogestrel-Ethinyl Estradiol 28 tablets (Desogestrel-Ethinyl Estradiol 28 tablets) — The Hospital for Sick Children. Desogestrel-ethinyl estradiol is a combined oral contraceptive that prevents ovulation by suppressing gonadotropin hormones and thickening cervical mucus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Desogestrel-Ethinyl Estradiol 28 tablets TARGET	Desogestrel-Ethinyl Estradiol 28 tablets	The Hospital for Sick Children	phase 3	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Levonorgestrel/Ethinyl Estradiol	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	Hansoh BioMedical R&D Company	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Ortho Tri Cyclen	Ortho Tri Cyclen	Virginia Commonwealth University	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Kariva®	Kariva®	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Etonogestrel/ethinyl estradiol vaginal ring	Etonogestrel/ethinyl estradiol vaginal ring	Andrea Roe, MD, MPH	marketed	Combined hormonal contraceptive	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

1. University of Palermo · 3 drugs in this class
2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
3. Organon and Co · 2 drugs in this class
4. HRA Pharma · 1 drug in this class
5. Hansoh BioMedical R&D Company · 1 drug in this class
6. Helsinki University Central Hospital · 1 drug in this class
7. Hoffmann-La Roche · 1 drug in this class
8. IVI Madrid · 1 drug in this class
9. Leiden University Medical Center · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class